Antimicrobial Resistance (AMR) occurs when pathogens change and find ways to resist the effects of antimicrobial agents. The pathogens survive, grow and spread their resistance. This process of adaption leads to AMR.1
Antimicrobial Resistance, particulary in Gram-negative bacteria, is widely recognised as one of the biggest threats to global health today, with the potential to affect anyone, of any age, in any country.2,3,4
Globally, AMR causes 700,000 deaths annually. Without actions by governments, industry and society, AMR is expected to cause 10 million deaths by 2050 - more than currently die from cancer.3
How Pfizer is helping address AMR
Pfizer has one of the industry's largest and most diverse portfolios of antimicrobials and is proud to be taking a lead in the fight to tackle AMR.5 We are deeply committed to working closely with the infectious disease community to address AMR6 through5:
|Active stewardship: to ensure patients recieve the correct antibiotic, according to independent guidelines, only if needed and for the right duration7|
|Innovative surveillance tools: to help physcians better understand current resistance patterns|
|Global policy leadership: to facillitate antibiotic development and proper use|
|Diverse portfolio: medicines and vaccines to treat and help prevent serious infections around the world|
|Manufacturing: responsible practices that do not harm human health or the environment|
AMR Action Fund
Pfizer have pledged US $100 million to the Antimicrobial Resistance (AMR) Action Fund which launched in July 2020, to help address the significant gloabl public health need for new antibiotics due to the rapid rise of antibiotic resistant infections.
The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies, philanthropies, development banks and multilateral organisations to re-invigorate and accelerate antibiotic development.8
Pfizer's commitment to a sustainable future
A strong pipeline of new antibiotics is essential to restoring the balance against increasing rates of AMR. However, investing in antibiotic research has long been unattractive for life science companies and no new class of antibiotics have been invented for decades.1
The journey from discovery to a clinically approved medicine is long and failure rate is high. The complexity and uncertainty in the early stages of discovery mean that huge sums have to be invested before a new antibiotic is successfully developed. New medicines may be kept in reserve for later use and therefore used infrequently, making it difficult to recover the high costs associated with development.9
At Pfizer, we're committed to working with the UK government, Department of Health and Social Care and other policy makers to develop a new model which ensures appropriate use of antibiotics, reduces the financial impact of infections and outbreaks and encourages a more sustainable economic model.
EEPRU developed and proposed a new framework which should be the basis of a value assessment for antibiotics, including additional elements of value such as; Diversity-, Insurance-, Enablement-, Transmission and Spectrum- value which are not typically included in traditional Health Technology Assessment (HTA) frameworks.
Building off this framework Pfizer developed a model that captures not only those criteria that are routinely included in HTA frameworks (Direct health costs & effects), but also several of the additional value elements outline by EEPRU, including; Transmission- and Diversity value by modelling the dynamics of infection and resistance within the wider population with a flexible treatment pathway. While this model is not proposed to be the only way forward we believe it will help accelerate the thinking required to continue to progress. The model has been shared widely across industry, presented via the APBI collaboration and discussed with EEPRU. The model is also available online, having been published through PharmacoEconomics.
Since our pioneering work on penicillin in the 1940s, we have had a long and proud heritage of addressing evolving infectious disease challenges, developing vaccines and anti-infective medicines that continue to improve the lives of patients around the globe. Today, Pfizer is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products across a wide number of countries, including low- and middle-income countries. With our innovative vaccine portfolio and pipeline, Pfizer is dedicated to helping to protect lives across all stages of life and to fight serious infectious diseases worldwide.5
Pfizers heritage in Anti-infectives
Learn more about our Heritage in Anti-infectives
- Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. May 2016. Available at: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf [Last accessed July 2020]
- World Health Organization. WHOs first global report on antibiotic resistance reveals serious, worldwide threat to public health. April 30 2014. Available at: https://www.who.int/mediacentre/news/releases/2014/amr-report/en/ [Last accessed July 2020]
- World Health Organization. Antibiotic Resistance Factsheet. February 2018. Available at: https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance [Last accessed July 2020]
- Vasoo S et al. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clinic Proc. 2015;90:395-403.
- Pfizer Annual Review 2018. Available at: https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2018/assets/pdf/pfizer-2018-annual-review.pdf [Last accessed July 2020]
- Pfizer Policy position in antimicrobial resistance (AMR) August 2017. Available at: http://pfe-pfizercom-d8-prod.s3.amazonaws.com/about/Policy-Position-on-Antimicrobial-Resistance-8-17-17.pdf [Last accessed July 2020]
- Davey P, Marwick CA, Scott CL, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane database Syst Rev. 2017;2:Cd003543.
- Pfizer pledges $100 million to new industry fund to help fight growing threat of antimicrobial reistance. Available at: https://www.pfizer.co.uk/pfizer-pledges-100-million-new-industry-fund-help-fight-growing-threat-antimicrobial-resistance [Last accessed July 2020]
- ABPI response to details of new payment system for antibiotics. July 2019. Available at: https://www.abpi.org.uk/media-centre/news/2019/july/abpi-response-to-details-of-new-payment-system-for-antibiotics/ [Last accessed July 2020]
Zavicefta▼ (ceftazidime avibactam)
ZAVICEFTA® 2 g/0.5 g Powder for Concentrate for Solution for Infusion – SPC
Legal category: POM. Basic NHS price: 10 vial pack £857.00.
Cresemba 100mg hard capsules – SPC
Legal Category: POM. Basic NHS Cost:14 caps pack £599.28
Cresemba 200mg powder for concentrate for solution for infusion – SPC
Legal Category: POM Basic NHS Cost: 1 vial pack £297.84
Zinforo (ceftaroline fosamil)
Zinforo® 600 mg powder for concentrate for solution for infusion - SPC
Legal category: POM. Basic NHS cost: 10 vial pack £375.00
PP-AIP-GBR-0574. December 2020